Shan Fu

机构：Cell Technology (China), Zhejiang University

发表论文 132 篇 · 总被引 2170 次 · h-index 24

代表论文

• Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial (2025 · Nature Medicine · 被引 58)
• Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (2025 · Journal for ImmunoTherapy of Cancer · 被引 14)
• OsWRKY18 , a WRKY transcription factor, is involved in rice salt tolerance (2025 · Plant and Cell Physiology · 被引 10)
• Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia (2025 · Experimental Hematology and Oncology · 被引 9)
• Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result (2025 · Journal of Advanced Research · 被引 7)
• On-treatment serum albumin levels can predict 28-day mortality and guide albumin infusion in sepsis patients (2025 · Frontiers in Medicine · 被引 5)